In recent studies, treatment of the NSCLC with PCA has been shown to inhibit FAK, MAPK, and NF-κB gene expressions, resulting in decreased production of cytokines and growth factors, thus preventing NSCLC cell proliferation4,5. This evidence concerns the gene PTK2 and non-small cell lung carcinoma.